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Background
The current literature suggests that psychiatric patients
have increased mortality and morbidity rates compared
with the general population, primarily due to cardiovas-
cular disease. There is increasing evidence that the use of
second-generation antipsychotics is associated with an
elevated risk in the appearance of metabolic abnormali-
ties, which promote the risk of cardiovascular disease.
Abdominal obesity seems to play a contributory role in
the conferring risk for hyperglycemia and dyslipidaemia.
Materials and methods
40 patients, all males, who are now hospitalized in the
Psychiatric Hospital of Thessaloniki, were studied. Their
mean age is 43 years old (25-78) and they are all on treat-
ment for at least 1 year with second-generation antipsy-
chotics. 33 are heavy smokers and only one exercise twice
a week.
Results
The mean waist circumference is 109.1 cm (ranging from
85 to 131 cm) and for 32 (80%) of them is above 102 cm.
The mean BMI is 29.5 and in 36 (90%) cases is above 25
(BMI>25=overweight). 6 (15%) of them have high glu-
cose level(>110mg/dl), 18 (30%) have high total choles-
terol (>200mg/dl) and the mean blood pressure is
estimated about 130/85 mmHg. 14 patients have triglyc-
erides above normal (>150mg/dl) and 8 have low HDL
levels (<40mg/dl). 8 patients need antihypertensive, 4
hypoglycemic and 2 hypolipidemic drugs. In sum, 14
patients (35%) need treatment for the metabolic distur-
bances, probably caused by the use of the SGAs.
Conclusions
Literature review and evidence from our study show the
important role of weight-gain in psychiatric patients, as it
is associated with a variety of adverse physiological effects,
including changes in plasma glucose and lipid levels.
Therefore, ongoing monitoring for patients who are being
treated with SGAs and careful selection of treatment in
high-risk patients is needed.
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